SMARCA4 and lung carcinoma: In this case, the patient received combined immunotherapy with carrelizumab, achieving good efficacy, not only reaffirming that immune inhibitors can effectively treat poorly differentiated lung cancer with partial BRG-1 deficiency but also providing a new option that is more economical and accessible for Chinese patients.